Stratum corneum levels of calprotectin proteins S100A8/A9 correlate with disease activity in psoriasis patients
Stratum corneum levels of calprotectin proteins S100A8/A9 correlate with disease activity in psoriasis patients
复制标题
DOI：
10.1111/1346-8138.16032
复制
发表时间：
2021-06-24
影响因子：
3.1
通讯作者：
Ishiko, Akira
中科院分区：
文献类型：
--
作者：
Matsunaga, Yukiko;Hashimoto, Yuki;Ishiko, Akira
银屑病是一种顽固性炎症性皮肤病，其特征是鳞状红斑和斑块。银屑病面积和严重程度指数（PASI）被广泛用于评分疾病的严重程度，但评估是主观的，客观的生物标志物将是有用的。可以非侵入性采集的角质层（SC）可以反映表皮角质形成细胞中银屑病相关的变化，例如钙卫蛋白S100 A8和S100 A9的上调。本研究的目的是检查SC中S100 A8/A9蛋白水平作为银屑病疾病活动性生物标志物的可用性。53例银屑病患者、30例寻常型银屑病（PsV）患者和23例银屑病关节炎（PsA）患者参加了研究。通过胶带剥离收集来自病变和非病变皮肤的SC细胞。采用酶联免疫吸附试验定量测定血清和SC中S100 A8/A9水平，并与治疗开始或转换前后的PASI评分进行比较。特应性皮炎（AD）患者和无病个体用作对照。S100 A8/A9在银屑病皮损皮肤SC中的表达显著高于非皮损皮肤和AD皮肤。PsV和PsA患者的SC S100 A8/A9水平无显著差异。银屑病患者SC中S100 A8/A9水平与PASI评分呈显著正相关。当患者的皮肤病变响应于治疗而清除（PASI清除）时，SC中S100 A8/A9的表达不再可检测。SC中S100 A8/A9蛋白水平可作为银屑病活动的客观、非侵入性生物标志物，以补充PASI评分。
Psoriasis is an intractable inflammatory skin disorder characterized by scaly erythema and plaques. The Psoriasis Area and Severity Index (PASI) is widely used to score disease severity, but evaluation is subjective, and an objective biomarker would be useful. The stratum corneum (SC), which can be non-invasively harvested, may reflect psoriasis-associated changes in epidermal keratinocytes, such as the upregulation of the calprotectin proteins S100A8 and S100A9. The aim of this study was to examine the availability of S100A8/A9 protein levels in SC as a biomarker of psoriasis disease activity. Fifty-three patients with psoriasis, 30 with psoriasis vulgaris (PsV), and 23 with psoriatic arthritis (PsA) participated. SC cells from lesional and non-lesional skin were collected by tape-stripping. S100A8/A9 levels in serum and in SC were quantified by enzyme-linked immunosorbent assay and compared with PASI score before and after treatment initiation or switching. Atopic dermatitis (AD) patients and disease-free individuals were used as controls. Expression of S100A8/A9 in SC of lesional skin of psoriasis patients was significantly higher than in non-lesional skin or AD skin. There was no significant difference of SC S100A8/A9 levels between PsV and PsA patients. The S100A8/A9 levels in SC of psoriasis patients were significantly positively correlated with the PASI score. When patients' skin lesions cleared (PASI clear) in response to treatment, expression of S100A8/A9 in SC was no longer detectable. S100A8/A9 protein levels in SC may be available as an objective, non-invasive biomarker of psoriasis activity to complement PASI scoring.